🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Stocks - Apple Falls in Premarket; Drug Reports Lift Gilead, AbbVie

Published 03/02/2020, 14:04
Updated 03/02/2020, 14:27
© Reuters.
BA
-
GS
-
GILD
-
RYAAY
-
AAPL
-
CHKP
-
NOC
-
ABBV
-

By Geoffrey Smith

Investing.com -- Stocks in focus in premarket trade on Monday, 3rd February. Please refresh for updates

8:21 AM ET: Northrop Grumman (NYSE:NOC) stock fell 1.6% after receiving a double-downgrade to Sell from Buy from analysts at Goldman Sachs (NYSE:GS).

8:24 AM ET: Ryanair ADRs (NASDAQ:RYAAY) were in focus after the company’s common stock rose 5.4% in London on the back of a better-than-expected end to 2019. Europe’s largest discount airline returned to profit, but pushed back its medium-term traffic target due to the delayed receipt of Boeing (NYSE:BA) 737 MAXes.

  • 8:14 AM ET: Check Point Software (NASDAQ:CHKP) stock was down 1.7% despite reporting what appeared to be marginally better than expected numbers for the fourth quarter. The cyber security firm initially gave no guidance for the current year but will hold a conference call at 8:30 AM ET.
    • 8:10 AM ET: Apple (NASDAQ:AAPL) stock fell 0.7% to a three-week low after the company said it would shut its stores, corporate offices and call centers in China until at least Feb. 9, out of what it called “an abundance of caution” over the coronavirus outbreak. The company makes some 20% of its iPhone sales in China. In addition to the sales issue, the company also faces possible supply-chain issues as the Chinese government has ordered factories around the country to stay shut until Feb. 10.

    • Boeing (NYSE:BA) stock was up 0.1% despite suggestions of further complications to the process of getting the 737 MAX airborne again. The New York Times reported that European regulators want the company to relocate certain stretches of wiring to reduce the risk of short-circuiting. The Wall Street Journal said that the Federal Aviation Agency, which disagrees with its European counterpart, may push back a key certification flight as a result.

    • AbbVie (NYSE:ABBV) stock was up 1.2% after reports that its antiviral products were part of a cocktail of drugs successfully used to treat a patient suffering from the novel coronavirus in Thailand.

    • Gilead Sciences (NASDAQ:GILD) stock was up 5.3% after saying late on Friday that a U.S. coronavirus patient had responded positively to treatment with the company’s anti-HIV drug remdesivir, which hasn’t yet received regulatory approval in the U.S. or anywhere else.

    Latest comments

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.